The company has presented data from two patients with liver metastases of colorectal cancer origin treated with ACT in the clinical Phase I ACTIVATE trial.
The presented radiological results from these two patients suggest an improved response to standard of care chemotherapy in the tumors that are exposed to ACT treatment. This aligns well with the preclinical evidence that ACT treatment can enhance the response to several chemotherapies in different cancer models, describes the company. Based on the initial clinical results, ACT treatment does not add to the safety or tolerability burden on patients. No adverse events considered related to the ACT treatment were seen in these two patients when ACT was combined with standard of care chemotherapy, states the company.
The results also suggest a positive tumor response associated with the ACT treatment. This trial will set the stage for diversifying the use of this technology platform to a wide range of systemic therapies across multiple tumor types.”
“Results of the Phase I study have given us several insights, most importantly that the treatment did not reveal any unexpected side effects either on its own or worsen the side effects of chemotherapy in the treated patients. The results also suggest a positive tumor response associated with the ACT treatment. This trial will set the stage for diversifying the use of this technology platform to a wide range of systemic therapies across multiple tumor types,” says the principal investigator of the ACTIVATE study, Prof. Dr. Udai Banerji.
The Phase I ACTIVATE trial
So far, seven patients have been enrolled in the study and encouraging insights have been gained from these patients, states the company.
EXACT Therapeutics is now in the process of completing the dose-escalation part of the study and will thereafter randomize up to 20 patients to two dose levels of ACT in an expansion part of the Phase I ACTIVATE trial.